Spyre Therapeutics CEO Trims Position Amid Clinical Catalyst Acceleration

Cameron Turtle, CEO of Spyre Therapeutics (NASDAQ: SYRE), executed a sale of 15,000 common shares on April 1, 2026. The transaction, valued at roughly $740,000 based on a weighted average price of $49.33, was conducted under a Rule 10b5-1 trading plan established in June. The sale represents a modest 2.33% reduction in Turtle's direct holdings, leaving him with 627,540 shares. This activity follows a significant rally in the company's stock, which has surged approximately 300% over the last year, suggesting the move is routine profit-taking rather than a shift in fundamental conviction. Spyre is a biotechnology firm with a $4 billion market capitalization, specializing in monoclonal antibody technology and combination therapies for inflammatory bowel disease and other autoimmune conditions. The company's strategic focus remains on early-stage development and long-term value creation. Market attention is now shifting toward the company's clinical pipeline. The SKYWAY rheumatoid arthritis sub-study is now expected to provide topline data in Q3 2026, as enrollment was completed ahead of schedule. Further readouts for axial spondyloarthritis and psoriatic arthritis are slated for Q4, while the SKYLINE ulcerative colitis platform continues to enroll patients ahead of plan. This dense cadence of upcoming data releases is expected to be the primary driver of the company's valuation in the coming quarters.